Cricket Australia has suspended veteran fast bowler Megan Schutt and opened an internal investigation after media reports and a Cricket Australia statement said the 31-year-old has been accused of the improper use of prescription medication outside competition. The development was reported on October 23, 2026 and represents a significant disciplinary matter involving a current international player.
What happened and when
Cricket Australia announced that Schutt is suspended from all Cricket Australia - sanctioned activities pending the outcome of an investigation into alleged improper use of prescription medication outside competition. The actions and the initial reporting took place on October 23, 2026. The organisation said the suspension is an interim measure while it examines the circumstances and gathers relevant information.
Verified facts and sources
Two independent news outlets reported the suspension and attributed details to Cricket Australia’s statement or reporting: national and major sports news bulletins published or updated on October 23, 2026 noted the suspension and described the allegation as related to prescription medication used improperly outside competition. Those reports are the basis for this article’s verified facts.
Immediate consequences for Schutt and her teams
- Schutt is not available for selection in any Cricket Australia - governed matches or team activities while the interim suspension remains in place.
- Cricket Australia will conduct an investigation and determine whether further disciplinary steps are warranted after it completes fact-finding.
- The suspension may affect squad planning and selection for upcoming fixtures involving Australia’s women’s teams until the matter is resolved.
Context, why this matters
Megan Schutt is one of Australia’s leading seam bowlers and a high-profile member of the national team. Any suspension of a current international player for alleged anti-doping or medication-related breaches is significant because it touches on player welfare, team availability and the integrity frameworks that govern elite sport.
Cricket Australia, like other national sporting bodies, enforces rules designed to ensure medicines and substances are used appropriately and that any required therapeutic-use exemptions (TUEs) are obtained when permitted medications are needed by athletes. Allegations about the improper use of prescription medication outside competition typically require careful investigation to establish facts, intent, and any breach of the applicable anti-doping code or internal regulations.
Confirmed next steps
- Cricket Australia will complete a formal inquiry and determine whether the allegation constitutes a breach of its policies or of the relevant anti-doping rules.
- Schutt will remain suspended from Cricket Australia activities during the inquiry.
- Cricket Australia may announce further disciplinary measures, clear the player, or refer the matter to an anti-doping authority depending on its findings.
What we do and do not yet know
Known: Cricket Australia has imposed an interim suspension and initiated an investigation into alleged improper use of prescription medication outside competition; the reporting and the organisational response were published on October 23, 2026.
Unconfirmed: Public reporting so far has not published detailed medical information, the specific medication involved, whether a therapeutic-use exemption was in place, or whether an external anti-doping organisation has been formally notified. Those details may be revealed later as the investigation proceeds or if formal charges are filed.
Looking ahead
The coming days should clarify whether Cricket Australia’s internal inquiry results in further action and how this will affect Schutt’s availability for selection. Given the profile of the player and the national team, broadcasters, selectors and fans will closely watch any formal outcomes and statements from Cricket Australia or relevant anti-doping authorities.
We will update this report as Cricket Australia or other authoritative sources publish further information.
